Effects of Dapagliflozin on Cardiovascular Risk Factors

References

• . Diabetes and Coronary Heart Disease. Diabetes Spectr. 1999;12(2):80–83
   Google Scholar
• . American Heart Association. Cardiovascular disease and diabetes. http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp. January 31, 2013. Accessed April 29, 2013
   Google Scholar
• . Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241(19):2035–2038
   PubMed Web of Science ®Google Scholar
• . Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234
   PubMed Web of Science ®Google Scholar
• . Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA. 1982;248(12):1465–1477
   PubMedGoogle Scholar
• . Stratton IM, Adler AI, Neil HA . Association of glycaemia with macro vascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412
   PubMed Web of Science ®Google Scholar
• . Elley CR, Kenealy T, Robinson E, Drury PL. Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. Diabet Med. 2008;25(11):1295–1301
   PubMedGoogle Scholar
• . Selvin E, Marinopoulos S, Berkenblit G, . Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–431
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Cleary PA, Backlund JY, . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653
   PubMed Web of Science ®Google Scholar
• . Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589
   PubMed Web of Science ®Google Scholar
• . Patel A MacMahon S, Chalmers J, . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572
   PubMed Web of Science ®Google Scholar
• . Duckworth W, Abraira C, Moritz T, . Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139
   PubMed Web of Science ®Google Scholar
• . Gerstein HC, Miller ME, Byington RP, . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471
   PubMed Web of Science ®Google Scholar
• . Cohen D. Rosiglitazone: what went wrong? BMJ. 2010;341:c4848
   Google Scholar
• . Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vase Biol. 2008;28(4):629–636
   PubMed Web of Science ®Google Scholar
• . Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens. 1993;11(3):319–325
   PubMedGoogle Scholar
• . Scott R, Donoghoe M, Watts GF, . Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovasc Diabetol. 2011;10:102
   PubMed Web of Science ®Google Scholar
• . Hansson L, Zanchetti A, Carruthers SG, . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755–1762
   PubMed Web of Science ®Google Scholar
• . Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393
   PubMed Web of Science ®Google Scholar
• . Vaag AA. Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study. Endocr Pract. 2006;12( suppl 1):89–92
   PubMedGoogle Scholar
• . Australian Government, Department of Health and Ageing, Therapeutic Goods Administration. Australian public assessment report for dapagliflozin propanediol monohydrate, http://www.tga.gov.au/pdf/auspar/auspar-dapagliflozin-propanediol-monohydrate-130114.pdf. January 2013. Accessed April 29, 2013
   Google Scholar
• . Forxiga [package insert]. London, UK: Bristol-Myers Squibb/AstraZeneca; 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summaryfor_the_public/human/002322/WC500136025.pdf. Accessed April 29, 2013
   Google Scholar
• . US Food and Drug Administration. FDA NEWS RELEASE: FDA approves Invokana to treat type 2 diabetes. http://www.fda.gov/News-Events/Newsroom/PressAnnouncements/ucm345848.htm. March 29, 2013. Accessed April 12, 2013
   Google Scholar
• . Bristol-Myers Squibb, AstraZeneca. Background document: Dapagliflozin. US FDA Endocrinologic and Metabolic Advisory Committee. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262996.pdf. June 13, 2011. Accessed April 29, 2013
   Google Scholar
• . Bolinder J, Ljunggren O, Kullberg J, . Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–1031
   PubMed Web of Science ®Google Scholar
• . Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–2233
   PubMed Web of Science ®Google Scholar
• . Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11(1):43
   PubMed Web of Science ®Google Scholar
• . Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217–2224
   PubMed Web of Science ®Google Scholar
• . Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928–938
   PubMed Web of Science ®Google Scholar
• . Wilding JP, Woo V, Soler NG, . Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405–415
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Del Prato S, Meier JJ, . Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015–2022
   PubMed Web of Science ®Google Scholar
• . Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446–456
   PubMed Web of Science ®Google Scholar
• . Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566–1575
   PubMedGoogle Scholar
• . Klein S, Sheard NF, Pi-Sunyer X, . Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 2004;27(8):2067–2073
   PubMed Web of Science ®Google Scholar
• . Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162(16):1867–1872
   PubMedGoogle Scholar
• . Centers for Disease Control and Prevention. Prevalence of Overweight and Obesity Among Adults with Diagnosed Diabetes—United States, 1988–1994 and 1999–2002. MMWR Morb Mortal Wkly Rep. 2004;53(45):1066–1068
   PubMedGoogle Scholar
• . List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650–657
   PubMed Web of Science ®Google Scholar
• . Turner RC, Millns H, Neil HA, . Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316(7134):823–828
   PubMed Web of Science ®Google Scholar
• . Chirovsky DR, Fedirko V, Cui Y, Sazonov V, Barter P. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. Eur J Cardiovasc Prev Rehabil. 2009;16(4):404–423
   PubMedGoogle Scholar
• . Mansia G, De Backer G, Dominiczak A, . 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007;16(3):135–232
   PubMed Web of Science ®Google Scholar
• . Woo V, Langkilde AM, Sugg J, Parikh S. Dapagliflozin, a novel antihyperglycemic agent that promotes urinary glucose excretion, reduces systolic blood pressure in patients with type 2 diabetes mellitus. Presented at: 84th Annual Scientific Sessions of the American Heart Association; November 12–16, 2011; Orlando, Florida, USA
   Google Scholar
• . Nauck MA, Del Prato S, Rohwedder K, Theuerkauf A, Langkilde AM, Parikh S. Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin: 2-year results. Presented at: 71st Scientific Sessions of the American Diabetes Association; June 24–28, 2011; San Diego, CA
   Google Scholar
• . Strojek K, Hruba V, Elze M, Langkilde AM, Parikh S. Efficacy and safety of dapagliflozin as an add-on to glimepiride in T2DM inadequately controlled with glimepiride alone over 48 weeks. Presented at: International Diabetes Federation; December 4–8, 2011; Dubai, UAE
   Google Scholar
• . Woo V, Tang W, Salsali A, List JF. Long-term efficacy of dapagliflozin monotherapy in patients with type 2 diabetes mellitus. Presented at: International Diabetes Federation; December 4–8, 2011; Dubai, UAE
   Google Scholar
• . Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol. 2007;2(3):581–590
   PubMed Web of Science ®Google Scholar
• . Sarnak MJ, Levey AS, Schoolwerth AC, . Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154–2169
   PubMed Web of Science ®Google Scholar
• . Ptaszynska A, Chalamandaris A-G, Sugg J, Johnsson K, Parikh S, List J. Effects of dapagliflozin on renal function. Presented at: 72nd Scientific Sessions of the American Diabetes Association; June 8–12, 2012; Philadelphia, PA
   Google Scholar
• . Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein Mortality RISk study (AMORIS). J Intern Med. 2009;266(6):558–570
   PubMed Web of Science ®Google Scholar
• . Sinan Deveci O, Kabakci G, Okutucu S, . The association between serum uric acid level and coronary artery disease. Int J Clin Pract. 2010;64(7):900–907
   PubMedGoogle Scholar
• . Kanbay M, Huddam B, Azak A, . A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6(8):1887–1894
   PubMed Web of Science ®Google Scholar
• . Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid—a facet of hyperinsulinaemia. Diabetologia. 1987;30(9):713–718
   PubMedGoogle Scholar
• . Marchioli R, Finazzi G, Specchia G, . Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33
   PubMed Web of Science ®Google Scholar
• . Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003;59(3):538–548
   PubMed Web of Science ®Google Scholar
• . Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13):4272–4290
   PubMedGoogle Scholar
• . Bunn HF. New agents that stimulate erythropoiesis. Blood. 2007;109(3):868–873
   PubMed Web of Science ®Google Scholar
• . Ptaszynska A, Johnsson K, Apanovitch A-M, Sugg J, Parikh S, List J. Safety of dapagliflozin in clinical trials for T2DM. Presented at: 72nd Scientific Sessions of the American Diabetes Association; June 8–12, 2012; Philadelphia, PA
   Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Salsali A, Tang W, List JF, Ferrannini E. Efficacy of Dapagliflozin as Monotherapy Administered in the Morning or Evening to Treat Type 2 Diabetes Mellitus. Presented at: 46th Annual Meeting of the European Association for the Study of Diabetes; September 20–24, 2010; Stockholm, Sweden
   Google Scholar